Aurealis Therapeutics will be presenting during the European Wound Management Association (EWMA) 2023 Conference

Aurealis Therapeutics is excited to sponsor the European Wound Management Association (EWMA) 2023 Conference taking place in Milan, Italy from 3-5 May 2023. Our CEO Juha Yrjänheikki, COO Laurent Décory, and CMO Haritha Samaranayake and will be attending the conference.

We will actively participate several parts of the event:

  • On the 4th of May, Laurent Décory, COO of Aurealis Therapeutics, will co-chair Preparing for successful wound care clinical trials during EWMA Innovation Forum, with renowned speakers Kirsi Isoherranen, Simone Barbagallo and Alberto Piaggesi.
  • On the 5th of May, Professor Christoph Schindler will present the results of AUP-16 DFU Phase 1 study and abstract 4-in-1 live biotherapeutic Gene Therapy Medicinal Product (GTMP) accelerates healing of Diabetic Foot Ulcers (DFU): a first-in-human, phase-1 clinical study during the Diabetic Foot session number 5.
  • During the same day, Laurent Décory will present Aurealis Therapeutics company and platform during EWMA Innovation Forum pitch session number 3.


Check the scientific program here.

Participants to these sessions will be required to have a previous registration. Thus, it is important to save your place.

We look forward to meeting you in Milan!

About Aurealis Therapeutics

Aurealis Therapeutics AG is a Swiss-Finnish private clinical-stage synthetic biology company focusing on the development of lactic acid bacteria -based GMO cell and gene therapies. The company’s lead clinical assets are the first-in-class four-in-one cell and gene therapies AUP-16 for chronic wounds and AUP-55 for cancers. Aurealis therapies are based on proprietary technology involving genetically engineered Lactococcus Cremoris acting as millions of small immune-activating bioreactors producing multiple human therapeutic proteins (cytokines, growth factors, antibody fragments) to effectively and safely re-educate the distorted host immune microenvironment to a proper state.

For more information:

Aurealis Therapeutics:

Laurent Décory, COO


Share the news:

other recent news: